Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Urology and Nephrology
Published in: International Urology and Nephrology 2/2008

01-06-2008 | Case Report

De novo nephrotic syndrome following pegylated interferon alfa 2b/ribavirin therapy for chronic hepatitis C infection

Authors: Jose L. Tovar, Maria Buti, Alfonso Segarra, Joaquim Majó, Rafael Esteban

Published in: International Urology and Nephrology | Issue 2/2008

Login to get access

Abstract

This paper describes the case of a patient with HCV, without previous evidence of nephropathy, who following two well-tolerated cycles of treatment with interferon alone developed nephrotic syndrome after a third attempt with ribavirin associated with peginterferon alfa 2b. The patient exhibited a total remission when the antiviral treatment was discontinued.
Literature
1.
Alter MJ, Kruszon-Moran D, Nainan OV et al (1999) The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Eng J Med 341:556–562CrossRef
2.
Kumar D, Wallington_Beddoe C, George J, Lin R, Samarasinhe D, Liddle C, Farrel G (2003) Effectiveness of interferon alfa 2b/ribavirin combination therapy for chronic hepatitis C in a clinical setting. Med J Aust 178:267–271PubMed
3.
Fried MW, Shiffman ML, Reddy RK, Smith C, Marinos G, Goncales FL et al (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975–982PubMedCrossRef
4.
Russo MW, Fried MW (2003) Side effects of therapy for chronic hepatitis C. Gastroenterology 124:1711–1719PubMedCrossRef
5.
Willson RA (2002) Nephrotoxicity of interferon alfa-ribavirin therapy for chronic hepatitis C. J Clin Gastroenterol 35:89–92PubMedCrossRef
6.
Bruchfeld A, Lindahl K, Stale L, Söderberg M, Schvarcz R (2003) Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 18:1573–1580PubMedCrossRef
7.
Covic A , Maftei I-D, Mardare NGI et al (2006) Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodyalisis patients: results from a large, multicenter audit. J Nephrol 19:794–801PubMed
8.
Gluud C, Gluud LL, Brok J (2006) Ribavirin monotherapy for chronic hepatitis C infection: a Chochrane hepato-biliary group systematic review and meta-analysis of randomised trials. Am J Gastroenrol 101:842–847CrossRef
9.
D’Amico G (1998) Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int 54:650–671PubMedCrossRef
10.
Ohta S, Yokoyama H, Wada T et al (1999) Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection and interferon therapy. Am J Kidney Dis 33:1040–1048PubMedCrossRef
11.
Clive DM, Stoff JS (1984) Renal syndromes associated with nonsteroidal antiinflamatory drugs. N Engl J Med 310:663–572CrossRef
12.
Schlam SW, Hanson BE, Chemello L et al (1997) Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C: meta-analysis of individual patient data from European centers. J Hepatol 26:961–966CrossRef
13.
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD et al (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958–965PubMedCrossRef
14.
Izzedine H, Lanuay-Vacher V, Bourry E et al (2006) Drug-induced glomerulopathies. Expert Opin Drug Saf 5:1–12CrossRef
15.
Brok J, Gluud LL, Gluud C (2005) Effects of adding ribavirin to interferon to treat chronic hepatitis C infection: a systematic review and meta-analysis of randomised trials. Arch Intern Med 165:2206–2212PubMedCrossRef
Metadata
Title
De novo nephrotic syndrome following pegylated interferon alfa 2b/ribavirin therapy for chronic hepatitis C infection
Authors
Jose L. Tovar
Maria Buti
Alfonso Segarra
Joaquim Majó
Rafael Esteban
Publication date
01-06-2008
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 2/2008
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-007-9241-7

Other articles of this Issue 2/2008

International Urology and Nephrology 2/2008 Go to the issue

Original Article

Relationship between aortic valve sclerosis and left ventricular hypertrophy in chronic haemodialysis patients

Original Article

Glomerulonephritis causing acute renal failure during the course of bacterial infections. Histological varieties, potential pathogenetic pathways and treatment

Letter to the Editor

Does ivabradine exhibit a role in the reduction of bladder overactivity?

Original article

Transurethral resection of ejaculatory ducts in the treatment of complete ejaculatory duct obstruction

Original Article

Supracostal access for percutaneous nephrolithotomy: less morbid, more effective

Original Article

Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits